Get the Stockscreener App
771.87
0.27%
-2.07
After Hours:
771.87
Regeneron Pharmaceuticals Inc stock is traded at $771.87, with a volume of 352.58K.
It is down -0.27% in the last 24 hours and down -1.07% over the past month.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
See More
Previous Close:
$773.94
Open:
$772
24h Volume:
352.58K
Relative Volume:
0.34
Market Cap:
$81.12B
Revenue:
$14.25B
Net Income/Loss:
$4.58B
P/E Ratio:
18.48
EPS:
41.7701
Net Cash Flow:
$3.88B
1W Performance:
-1.51%
1M Performance:
-1.07%
6M Performance:
+47.02%
1Y Performance:
+8.36%
1-Day Range:
$769.17
$775.00
1-Week Range:
$769.17
$788.01
52-Week Range:
$476.49
$792.77
Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile
Name
Regeneron Pharmaceuticals Inc
Sector
Industry
Phone
(914) 847-7000
Address
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Compare REGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
REGN
Regeneron Pharmaceuticals Inc
|
771.87 | 81.34B | 14.25B | 4.58B | 3.88B | 41.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
453.36 | 115.12B | 11.74B | 3.68B | 3.34B | 14.19 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.65 | 52.48B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
840.95 | 51.59B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
174.04 | 37.13B | 447.02M | -1.18B | -906.14M | -6.1812 |
Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-03-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-24-25 | Initiated | HSBC Securities | Buy |
| Nov-24-25 | Resumed | Truist | Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Perform |
| Aug-14-25 | Initiated | Rothschild & Co Redburn | Buy |
| Jun-30-25 | Downgrade | Argus | Buy → Hold |
| May-30-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| May-30-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-14-25 | Upgrade | Citigroup | Neutral → Buy |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Overweight |
| Feb-05-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jan-16-25 | Downgrade | UBS | Buy → Neutral |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Sep-24-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Mar-12-24 | Initiated | Bernstein | Outperform |
| Jan-12-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-03-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Aug-21-23 | Upgrade | Canaccord Genuity | Hold → Buy |
| Aug-21-23 | Reiterated | Oppenheimer | Perform |
| Jun-28-23 | Downgrade | Canaccord Genuity | Buy → Hold |
| Mar-27-23 | Upgrade | SVB Securities | Market Perform → Outperform |
| Mar-24-23 | Upgrade | Jefferies | Hold → Buy |
| Mar-23-23 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Jan-30-23 | Upgrade | Cowen | Market Perform → Outperform |
| Jan-20-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-26-22 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Oct-17-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Sep-09-22 | Upgrade | Jefferies | Underperform → Hold |
| Sep-09-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jul-25-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Neutral |
| Jun-06-22 | Initiated | Jefferies | Underperform |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Jan-05-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Jan-03-22 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Dec-15-21 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Dec-09-21 | Resumed | Wells Fargo | Overweight |
| Dec-07-21 | Resumed | Cowen | Market Perform |
| Dec-06-21 | Initiated | Goldman | Buy |
| Nov-19-21 | Resumed | BMO Capital Markets | Outperform |
| Nov-05-21 | Downgrade | The Benchmark Company | Buy → Hold |
| Jun-29-21 | Initiated | H.C. Wainwright | Buy |
| Jan-25-21 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jan-13-21 | Upgrade | The Benchmark Company | Hold → Buy |
| Jan-08-21 | Upgrade | Citigroup | Neutral → Buy |
| Oct-05-20 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Aug-20-20 | Downgrade | The Benchmark Company | Buy → Hold |
| Jul-09-20 | Upgrade | SunTrust | Hold → Buy |
| May-26-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Apr-28-20 | Downgrade | Citigroup | Buy → Neutral |
| Apr-17-20 | Upgrade | The Benchmark Company | Hold → Buy |
| Apr-08-20 | Initiated | The Benchmark Company | Hold |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Feb-26-20 | Upgrade | Canaccord Genuity | Hold → Buy |
| Feb-26-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Feb-25-20 | Upgrade | Jefferies | Hold → Buy |
| Feb-11-20 | Upgrade | Argus | Hold → Buy |
| Dec-24-19 | Initiated | Raymond James | Mkt Perform |
| Dec-16-19 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-13-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| Nov-12-19 | Initiated | SunTrust | Hold |
| Nov-07-19 | Upgrade | Citigroup | Neutral → Buy |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Sep-23-19 | Upgrade | Guggenheim | Neutral → Buy |
View All
Regeneron Pharmaceuticals Inc Stock (REGN) Latest News
Generate Investment Management Ltd Acquires 6,778 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
3 Reasons to Avoid REGN and 1 Stock to Buy Instead - FinancialContent
Simplify Asset Management Inc. Raises Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Rockland IDA votes to terminate and recapture Regeneron incentives - Westfair Communications
J&J Bispecific For Atopic Dermatitis Fails To Pass Muster - Citeline News & Insights
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
TB Alternative Assets Ltd. Increases Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Bellecapital International Ltd. Buys 2,276 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals Earnings Notes - Trefis
Cwm LLC Has $30.03 Million Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Beacon Investment Advisory Services Inc. - MarketBeat
Morgan Stanley Sees Policy Risks Receding for Regeneron (REGN) - Insider Monkey
Vontobel Holding Ltd. Has $5.83 Million Stock Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Will Regeneron Pharmaceuticals Inc. stock split attract more investorsMarket Sentiment Shifts & High Return Capital Gain - bollywoodhelpline.com
Exchange Traded Concepts LLC Purchases 1,369 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron (REGN): Revisiting Valuation After Japan’s Dupixent Pediatric Asthma Approval and Bullish Investor Positioning - simplywall.st
Regeneron Pharmaceuticals, Inc. $REGN Stake Lifted by Hunter Perkins Capital Management LLC - MarketBeat
Swedbank AB Cuts Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Bar Harbor Wealth Management Purchases 3,304 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
ARS Investment Partners LLC Increases Stock Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Brighton Jones LLC Buys 2,335 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
10 Best Debt Free Dividend Stocks to Buy Now - Insider Monkey
Does Regeneron Still Offer Value After Strong Five Year Share Price Gains? - Yahoo Finance
Sanofi Eczema Drug Linked To Lymphoma, Suit Says - Law360
Regeneron Pharmaceuticals's Options Frenzy: What You Need to Know - Benzinga
Regeneron Pharmaceuticals (NASDAQ:REGN) Sets New 1-Year HighHere's What Happened - MarketBeat
Regeneron stock reaches 52-week high at $791.00 By Investing.com - Investing.com Australia
Regeneron stock reaches 52-week high at $791.00 - Investing.com
Regeneron Pharmaceuticals Stock (REGN) Opinions on Dupixent Success and Pipeline Developments - Quiver Quantitative
Sanofi, Regeneron’s Dupixent approved in Japan for children with asthma (SNY:NASDAQ) - Seeking Alpha
Press Release: Sanofi and Regeneron’s Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthma - The Manila Times
Regeneron and Sanofi Announce Approval of Dupixent® for Asthma Treatment in Children Aged 6 to 11 in Japan - Quiver Quantitative
Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Regeneron Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Diabetic Retinopathy Market to See Booming Growth 2025-2032 | - openPR.com
Aug Final Week: Will Regeneron Pharmaceuticals Inc. stock benefit from M&A activityJuly 2025 Snapshot & Safe Swing Trade Setups - moha.gov.vn
Wedge Capital Management L L P NC Buys New Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Stock Holdings Lifted by Osaic Holdings Inc. - MarketBeat
Regeneron: The Turnaround Is Gaining Steam - Seeking Alpha
Published on: 2025-12-20 18:02:12 - Улправда
Voya Investment Management LLC Cuts Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Thrivent Financial for Lutherans - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Corient Private Wealth LLC - MarketBeat
Regeneron Pharmaceuticals (NASDAQ:REGN) Downgraded to Hold Rating by Wall Street Zen - MarketBeat
Should Regeneron’s Clarified Eylea Biosimilar Timeline Reshape How REGN Investors View Its Core Franchise? - simplywall.st
Alvotech and Teva Settle With Regeneron on U.S. Launch Timing for Eylea Biosimilar AVT06 - TipRanks
Published on: 2025-12-19 17:35:07 - Улправда
How interest rate cuts could boost Regeneron Pharmaceuticals Inc. stockSwing Trade & Daily Technical Forecast Reports - DonanımHaber
Goldman Sachs Adjusts PT on Regeneron Pharmaceuticals to $807 From $788, Maintains Buy Rating - marketscreener.com
Texas Permanent School Fund Corp Cuts Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Alvotech, Teva reach settlement with Regeneron over Eylea biosimilar AVT06 in U.S. (TEVA:NYSE) - Seeking Alpha
Regeneron Pharmaceuticals Inc Stock (REGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Regeneron Pharmaceuticals Inc Stock (REGN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| YANCOPOULOS GEORGE | Bd. Co-Chair, President & CSO |
Dec 09 '25 |
Option Exercise |
555.67 |
146,815 |
81,580,691 |
442,334 |
| SCHLEIFER LEONARD S | Bd. Co-Chair, President & CEO |
Dec 09 '25 |
Option Exercise |
555.67 |
172,723 |
95,976,989 |
369,668 |
| LAROSA JOSEPH J | EVP General Counsel and Secret |
Nov 20 '25 |
Option Exercise |
555.67 |
14,450 |
8,029,431 |
35,525 |
| Bassler Bonnie L | Director |
Nov 20 '25 |
Option Exercise |
371.40 |
760 |
282,264 |
2,308 |
| Bassler Bonnie L | Director |
Nov 20 '25 |
Sale |
750.00 |
760 |
570,000 |
1,548 |
0.10%
0.08%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):